<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME)." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5d/9575561/0ee1107e04c6/pai-30-14-g001.jpg"/> </div> <div class="text-side"> <h1>HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).</h1> <p>A–D, Case number 1 (Table 2): Nodular melanoma. A, H&amp;E (original magnification, ×20). B, H&amp;E (original magnification, ×200). C, DS for Melan A/PRAME (original magnification, ×200). D, DS for HMB45/PRAME (original magnification, ×200). The lesion showed diffuse nuclear staining for PRAME (4+) and cytoplasmatic 1 for both HMB45 and Melan A (this latter less intense). E–H, Case number 36 (Table 2): Blue nevus. E, H&amp;E (original magnification, ×20). F, H&amp;E (original magnification, ×200). G, DS for Melan A/PRAME (original magnification, ×200). H, DS for HMB45/PRAME (original magnification, ×200). The lesion showed diffuse cytoplasmatic staining for both HMB45 and Melan A (this latter less intense) but not nuclear one for PRAME (0). I–L, Case number 15 (Table 2): Nodal metastasis. I, H&amp;E (original magnification, ×20). J, H&amp;E (original magnification, ×200). K, DS for Melan A/PRAME (original magnification, ×200). L, DS for HMB45/PRAME (original magnification, ×200). The lesion showed diffuse nuclear staining for PRAME (4+) and cytoplasmatic one for both HMB45 and Melan A (this latter less intense). There are rare PRAME (+) inflammatory cells/lymphocytes resident in the lymph node, with no cytoplasmatic staining for both Melan A and HMB45. M–P, Case number 39 (Table 2): Dysplastic nevus (interdigital skin of the foot). M, H&amp;E (original magnification, ×20). N, H&amp;E (original magnification, ×200). O, DS for HMB45/PRAME (original magnification, ×200). P, DS for HMB45/PRAME (original magnification, ×400). The lesion showed strong and diffuse cytoplasmatic staining for HMB45 with rare cells positive for PRAME (1+). PRAME has been graded as previously described by Lezcano et al.2 DS indicates double staining; H&amp;E, hematoxylin and eosin; HMB45, Human Melanoma Black 45; Melan A/MART-1, Melanoma Antigen/Melanoma Antigen Recognized by T cells 1; PRAME, PReferentially expressed Antigen in MElanoma.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34508017/" target="_blank">34508017</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>